Changjiang Pharmaceutical Group Co., Ltd. (SHE:300391)
China · Delayed Price · Currency is CNY 0.1900
0.00 (0.00%)
Inactive · Last trade price on Apr 10, 2026
SHE:300391 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 21.74 | 8.3 | 15.2 | 17.47 | 107.7 | 139.42 |
Trading Asset Securities | - | - | - | - | - | 0.5 |
Cash & Short-Term Investments | 21.74 | 8.3 | 15.2 | 17.47 | 107.7 | 139.92 |
Cash Growth | 222.79% | -45.43% | -13.00% | -83.77% | -23.03% | -65.81% |
Accounts Receivable | 908.61 | 985.37 | 1,646 | 1,447 | 1,523 | 1,435 |
Other Receivables | 52.21 | 70.27 | 254.34 | 31.42 | 52.72 | 163.19 |
Receivables | 960.82 | 1,056 | 1,901 | 1,479 | 1,576 | 1,598 |
Inventory | 85.74 | 42.45 | 51.86 | 59.47 | 195.35 | 251.61 |
Prepaid Expenses | - | - | 0.02 | - | - | - |
Other Current Assets | 23.99 | 22.97 | 160.79 | 185.85 | 180.31 | 129.21 |
Total Current Assets | 1,092 | 1,129 | 2,129 | 1,742 | 2,059 | 2,119 |
Property, Plant & Equipment | 611.89 | 634.73 | 962.39 | 1,078 | 1,306 | 1,162 |
Goodwill | 16.37 | 16.37 | 236.07 | 675.43 | 701.73 | 701.73 |
Other Intangible Assets | 75.94 | 77.51 | 99.18 | 41.74 | 62.67 | 72.88 |
Long-Term Accounts Receivable | - | - | 2.21 | - | - | - |
Long-Term Deferred Tax Assets | - | - | 16.47 | 39.8 | 66.22 | 52.96 |
Long-Term Deferred Charges | 127.1 | 137.72 | - | 0.36 | 13.35 | 15.36 |
Other Long-Term Assets | - | 0.03 | 0.81 | 1.69 | 5.08 | 559.13 |
Total Assets | 1,924 | 1,996 | 3,446 | 3,579 | 4,214 | 4,683 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Accounts Payable | 234.61 | 223.27 | 358.51 | 199.55 | 642.86 | 604.2 |
Accrued Expenses | 24.37 | 165.54 | 138.08 | 116.79 | 135.38 | 117.16 |
Short-Term Debt | 207.95 | 656.69 | 587.3 | 607.37 | 586.06 | 537.69 |
Current Portion of Long-Term Debt | 56.5 | 94.14 | 78 | 46.4 | 21.91 | 114.5 |
Current Portion of Leases | - | 0.94 | 30.03 | 24.02 | 9.44 | - |
Current Income Taxes Payable | 124.13 | 40.05 | 40.21 | 40.24 | 44.07 | 32.3 |
Current Unearned Revenue | 18.02 | 23.09 | 16.95 | 14.48 | 13.27 | 28.11 |
Other Current Liabilities | 1,534 | 720.91 | 631.34 | 496.21 | 656.93 | 1,193 |
Total Current Liabilities | 2,200 | 1,925 | 1,880 | 1,545 | 2,110 | 2,627 |
Long-Term Debt | 375.25 | 444.4 | 518.89 | 335.83 | 312.49 | 340 |
Long-Term Leases | - | 1.39 | 5.45 | 5.97 | 21.15 | - |
Long-Term Unearned Revenue | 14.72 | 14.96 | 15.89 | 15.9 | 23.71 | 26.08 |
Long-Term Deferred Tax Liabilities | 1.18 | 1.6 | 7.1 | 7.1 | 8.71 | 10.95 |
Other Long-Term Liabilities | 0.11 | 30.08 | 0.68 | 4.1 | 129.2 | 229.6 |
Total Liabilities | 2,591 | 2,417 | 2,428 | 1,914 | 2,605 | 3,234 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Common Stock | 350.34 | 350.34 | 350.34 | 350.34 | 350.34 | 350.34 |
Additional Paid-In Capital | 788.17 | 788.17 | 788.17 | 788.07 | 790.05 | 790.05 |
Retained Earnings | -1,781 | -1,571 | -943.39 | -337.73 | -314.46 | -363.57 |
Comprehensive Income & Other | - | - | - | - | 0.36 | -0.13 |
Total Common Equity | -642.57 | -432.84 | 195.12 | 800.67 | 826.28 | 776.69 |
Minority Interest | -25.04 | 11.49 | 822.2 | 863.95 | 783.01 | 672.79 |
Shareholders' Equity | -667.62 | -421.36 | 1,017 | 1,665 | 1,609 | 1,449 |
Total Liabilities & Equity | 1,924 | 1,996 | 3,446 | 3,579 | 4,214 | 4,683 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Total Debt | 639.69 | 1,198 | 1,220 | 1,020 | 951.04 | 992.19 |
Net Cash (Debt) | -617.95 | -1,189 | -1,204 | -1,002 | -843.34 | -852.27 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.76 | -3.39 | -3.44 | -2.86 | -2.41 | -2.43 |
Filing Date Shares Outstanding | 350.34 | 350.34 | 350.34 | 350.34 | 350.34 | 350.34 |
Total Common Shares Outstanding | 350.34 | 350.34 | 350.34 | 350.34 | 350.34 | 350.34 |
Working Capital | -1,108 | -795.29 | 248.2 | 196.6 | -50.96 | -508.19 |
Book Value Per Share | -1.83 | -1.24 | 0.56 | 2.29 | 2.36 | 2.22 |
Tangible Book Value | -734.89 | -526.72 | -140.13 | 83.5 | 61.88 | 2.08 |
Tangible Book Value Per Share | -2.10 | -1.50 | -0.40 | 0.24 | 0.18 | 0.01 |
Buildings | - | 779.09 | 895.16 | 990.62 | 1,063 | 488.18 |
Machinery | - | 114.09 | 101.36 | 93.78 | 302.2 | 296.27 |
Construction In Progress | - | - | 184.82 | 177.94 | 170.31 | 591.23 |